Drug Discovery & Pharmaceuticals

RSS

Pet ownership and care can support communication, wellbeing for people with aphasia

Feathers, fins or fur, all pets can make us feel happier. Now, new research from the University of South Australia shows that pet ownership and pet care can also support communication and wellbeing, especially for people with acquired language difficulties such as aphasia.

2 Aug 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023

Scientists discover a way to produce true structure of naturally-occurring anti-HIV compound

Having control over how a dish is cooked is always a good idea. Taking a hint from the kitchen, scientists appear to have discovered a way to produce a true structure of the rare but naturally-occurring anti-HIV compound Lancilactone C from start to finish.

28 Jul 2023

Using 'click chemistry' to create novel multi-protein anti-cancer agents

A potent anti-cancer therapy has been created using Nobel prize-winning "click chemistry", where molecules click together like LEGO bricks, in a new study by UCL and Stanford University researchers.

24 Jul 2023

Research reveals therapeutic potential of novel compound in inhibiting oncogene translation

Cutting-edge research at the Luxembourg Institute of Health reveals the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, opening up new therapeutic opportunities for leukemia patients.

24 Jul 2023

ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

21 Jul 2023

Researchers develop novel system to identify new therapeutics for familial hypercholesterolemia

The Mona Lisa, painted by the Italian artist Leonardo da Vinci, is one of the most recognizable paintings in the world. But many people would be surprised to learn that this painting offers the first evidence of a disease called familial hypercholesterolemia (FH).

20 Jul 2023

New mRNA-based malaria vaccine shows promise in preclinical trials

Trans-Tasman research collaborators from Te Herenga Waka-; Victoria University of Wellington's Ferrier Research Institute and the Malaghan Institute of Medical Research in New Zealand, and the Peter Doherty Institute for Infection and Immunity in Australia have developed an mRNA-based vaccine that can effectively target and stimulate protective immune cell responses against the malaria-causing parasite Plasmodium in preclinical models.

20 Jul 2023

Researchers achieve first-ever gram-scale synthesis of tanzawaic acid B

The discovery of antibiotics in 1928 was a major turning point in the history of medicine. For the first time since the dawn of human civilization, doctors had gained access to an extremely powerful and effective tool to fight against a wide variety of bacterial infections.

19 Jul 2023

Griffith University researchers develop new method to control virus assembly

Griffith University researchers have played a key role in using DNA 'origami' templates to control the way viruses are assembled.

17 Jul 2023

Insilico Medicine and MIKADO team up to find new treatments for cystinosis

A team led by researchers at the Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (Zurich, Switzerland) has used Insilico Medicine's generative artificial intelligence (AI) target discovery engine, PandaOmics, to identify actionable drug targets for the lysosomal storage disease cystinosis and to validate them in preclinical models of the disease.

14 Jul 2023

AI-powered drug discovery offers hope for cystinosis patients

Artificial intelligence is becoming increasingly important in drug discovery. Advances in the use of Big Data, learning algorithms and powerful computers have now enabled researchers at the University of Zurich (UZH) to better understand a serious metabolic disease.

14 Jul 2023

Quanterix launches LucentAD Biomarker blood test to aid physician diagnosis of Alzheimer’s disease in patients

Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD).

From Quanterix 14 Jul 2023

Purecap method offers hope for purer and safer mRNA vaccines

A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.

5 Jul 2023

Has COVID-19 changed the future of pharmaceutical regulation?

Has COVID-19 revolutionized the future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic? Our Head of Regulatory Affairs and Enhanced Services,

30 Jun 2023

Study shows promising prospects for automating 3D-DSRT in drug testing

The June 2023 issue of SLAS Discovery contains one review article, five full-length articles and two technical briefs covering spheroid models, 3D cell high-throughput screening (HTS) applications for treating Alzheimer's and other drug discovery research.

29 Jun 2023

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd., an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

From Albumedix Ltd. 29 Jun 2023

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

From Albumedix Ltd. 29 Jun 2023

Newly identified enzyme could be a useful tool for creating anticancer drugs

Many of the drugs we use to treat cancer and infectious disease are ⎯ or derive from ⎯ natural products, but it's difficult to know exactly how nature assembles them.

27 Jun 2023

A new approach for the synthesis of pharmaceutically relevant fluorinated phenanthridines

Phenanthridines are heterocyclic compounds consisting of two six-membered benzene rings fused to a six-membered ring containing nitrogen.

26 Jun 2023